Copyright © Inderes 2011 - present. All rights reserved.

Diamyd Medical

14.32 SEK

-0.83 %

Less than 1K followers

DMYD B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-0.83 %
-17.23 %
+27.18 %
+41.50 %
+22.60 %
+43.87 %
+3.33 %
-60.28 %
+376.90 %

Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.

Read more
Market cap
1.97B SEK
Turnover
7.7M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/3
2026

Interim report Q2'26

24/6
2026

Interim report Q3'26

7/10
2026

Annual report '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
More on that partnership: I truly believe that offers have been put on the table. However, the company has already gone through Big Pharma partnerships once, so why wouldn’t it succeed again with a targeted genetic population and a stronger effect. The company has been able to take...
2/17/2026, 1:08 PM
15
Diamyd Medical announces finalization of database for interim analysis in Phase 3 DIAGNODE-3 trial The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical’s ongoing pivotal Phase 3 trial (DIAGNODE-3) evaluating retogatein (rhGAD65...
2/24/2026, 11:47 AM
13
Good summary. A few thoughts that come to mind: First of all, I don’t believe a large portion of investors know how to interpret clinical papers accurately, nor do they spend time on it. And it’s not easy to separate the wheat from the chaff even if they did. The biotech scene is...
2/17/2026, 10:56 AM
12
Maybe being hooked up to IVs for two weeks and destroying the immune system isn’t very appealing. Jokes aside, the low sales are fully explained by the fact that at that stage, Tzield was only approved for Stage 2 treatment. In other words, for those who don’t yet have symptoms. ...
2/17/2026, 3:43 PM
9
A few reflections of my own: - Fundamentally, drug development is very high-risk and most companies fail right at the start. In Diamyd’s case, however, the groundwork has been done thoroughly, and that is why I am involved with a small amount. Let’s put it this way: I personally ...
2/17/2026, 8:20 AM
9
Fortunately, Tzield’s added value was enough, despite a horrible two-week hospital stay with its side effects and the same efficacy + exorbitant price. Yeah, and on top of that, lymphocyte depletion. And although the change observed during the Phase 2/3 study period is roughly in...
2/17/2026, 2:15 PM
5
Tzield sales are looking a bit sluggish, $16M in Q4 which was flat YoY. Perhaps this also tempers expectations for Diamyd.
2/17/2026, 2:30 PM
by Clark kent
4
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.